Tsung-Che Wu
@TsungCheWu
Followers
246
Following
104
Statuses
45
Medical oncologist @ NTUH in Taiwan, phase 1, GI cancer, HCC, BTC, ESCC, CRC, lung cancer Tsung-Che (Nathan) Wu
Taipei City, Taiwan
Joined December 2013
#GI25 Checkmate 8HW: dMMR/MSI-H CRC 1L 3Y PFS: Nivo/Ipi 68% vs Nivo 51% (HR 0.62). Groundbreaking—best 3Y PFS in any phase 3 advanced solid tumor IO study! •Biomarker harmonization in daily practice is key given ITT vs centrally confirmed cohort differences. •Combo shows superior efficacy, but mono offers 3Y progression-free for half, with less tox. •Urgent need for new biomarkers as traditional factors in subgroup analysis fail to guide. Game-changer, but still work to do! #crcsm @OncoAlert
0
1
10
RT @KoheiShitara: LEAP15 for gastric cancer did not meet OS endpoint. Drop of chemo or dose of LEN/toxicities matter? Need learn from nega…
0
10
0
@ehlJAMA @PTarantinoMD This is a 3-arm study, but the result of nivolumab monotherapy has not been reported.
0
0
0
RT @HHorinouchi: 🔥#ACLC24 @IASLC Asia🌏 🗣️Plenary 2: Frontiers in Lung Cancer Therapy: Addressing Today's Challenges and Tomorrow's Solution…
0
10
0
Atezolizumab + lurbinectedin vs Atezolizumab for 1L maintenance of SCLC Positive for PFS & OS #lcsm @OncoAlert @myESMO Amazing improvements for SCLC: IO for limited stage, tarlatamab, and promising B7-H3 & SEZ6 ADC emerge in such a short time!
0
1
6
@SuyogCancer There are a lot of great salvage options such as T-Dxd and SG for the control arm.
1
0
3
RT @KoheiShitara: Pleased to share final survival results of two phase 3 of zolbetuximab @NEJM which reinforce zolbetuxumab plus chemo as…
0
60
0
RT @tompowles1: Perioperative durvalumab + neoadjuvant chemo & cystectomy in operable bladder cancer significantly delays (HR 0.68) event f…
0
122
0
RT @DrChoueiri: Updated @NCCN guidelines (1.2025) are in, with some major changes for systemic therapies: 1) Ipi+Nivo is now a preferred re…
0
111
0
RT @saxotomy: Prof. Noboru Yamamoto of @NccriOfficial discussing the #mdm2 inhibitor #brigimadlin in #phaseI and #sarcoma & solid tumor pts…
0
2
0
RT @saxotomy: Prof. Jordi Rodon of @MDAndersonNews presenting the #syntheticlethality of the mtap pathway #EATOPIC @NtuhTw #ntucc
https://…
0
1
0
Insightful talk for combination immunotherapy by Josh Lin! #10thEATOPIC @NtuhTw
Prof. Josh Lin's brilliant insights of the challenges faced by #immunotherapy #combination and how to overcome them at the 10th #EATOPIC @NtuhTw
0
0
1
RT @saxotomy: Prof. Brigette Ma of @CUHKofficial sharing a excellent rev of #npc #drugdevelopment at 10th #EATOPIC meeting
0
1
0
RT @saxotomy: 10th EA-TOPIC in #NTUCC kick-off by the talk of Prof. James Yang #Taiwan #phaseItrials
0
2
0
RT @NatRevClinOncol: In a new Perspective article, Hung-Yang Kuo, @taxiforkab & Robert S. Kerbel discuss lessons learned from phase III cli…
0
19
0
Trastuzumab deruxtecan was granted tissue-agnostic approval for IHC 3+ HER2 IHC should be part of routine pathology exams for patients with advanced solid tumors In addition, data for rare cancer types not included in Destiny-Pantumor02 should be gathered! @myESMO @OncoAlert
0
0
3
Great news for patients with LS-SCLC! Durvalumab⬆️PFS & OS The first major advance in LS-SCLC since EP-CCRT was established Subsequent rather than concurrent IO may be a key Looking forward to seeing the HR, crossover, and tails #lcsm @myESMO @OncoAlert
0
0
5
RT @DrYukselUrun: Eagerly awaiting data from CM-274 at #EAU24 Adjuvant NIVOLUMAB showing improved OS in ITT and PD-L1 ≥1% urothelial cancer…
0
60
0